551 related articles for article (PubMed ID: 22309939)
61. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
[TBL] [Abstract][Full Text] [Related]
62. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
[TBL] [Abstract][Full Text] [Related]
63. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.
Spänkuch-Schmitt B; Bereiter-Hahn J; Kaufmann M; Strebhardt K
J Natl Cancer Inst; 2002 Dec; 94(24):1863-77. PubMed ID: 12488480
[TBL] [Abstract][Full Text] [Related]
64. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
65. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Tandle AT; Kramp T; Kil WJ; Halthore A; Gehlhaus K; Shankavaram U; Tofilon PJ; Caplen NJ; Camphausen K
Eur J Cancer; 2013 Sep; 49(14):3020-8. PubMed ID: 23790466
[TBL] [Abstract][Full Text] [Related]
67. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
68. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
69. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
70. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
71. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
Deng H; Jiang Q; Yang Y; Zhang S; Ma Y; Xie G; Chen X; Qian Z; Wen Y; Li J; Yang J; Chen L; Zhao X; Wei Y
Cancer Biol Ther; 2011 Feb; 11(4):401-9. PubMed ID: 21150280
[TBL] [Abstract][Full Text] [Related]
72. RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
Kolosenko I; Edsbäcker E; Björklund AC; Hamil AS; Goroshchuk O; Grandér D; Dowdy SF; Palm-Apergi C
J Control Release; 2017 Sep; 261():199-206. PubMed ID: 28684168
[TBL] [Abstract][Full Text] [Related]
73. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
[TBL] [Abstract][Full Text] [Related]
74. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
[TBL] [Abstract][Full Text] [Related]
75. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
76. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
[TBL] [Abstract][Full Text] [Related]
77. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
78. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
79. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.
van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
[TBL] [Abstract][Full Text] [Related]
80. Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
Medina-Aguilar R; Marchat LA; Arechaga Ocampo E; Gariglio P; García Mena J; Villegas Sepúlveda N; Martínez Castillo M; López-Camarillo C
Oncol Rep; 2016 Jun; 35(6):3696-704. PubMed ID: 27109433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
